Kerecis Revenue and Competitors
Estimated Revenue & Valuation
- Kerecis's estimated annual revenue is currently $237.2M per year.
- Kerecis's estimated revenue per employee is $351,400
- Kerecis's total funding is $93M.
Employee Data
- Kerecis has 675 Employees.
- Kerecis grew their employee count by 63% last year.
Kerecis's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Founder, Chairman & President | Reveal Email/Phone |
2 | VP Medical Collaboration and Engagement | Reveal Email/Phone |
3 | SVP for Research & Development | Reveal Email/Phone |
4 | VP Surgical & Burn Sales | Reveal Email/Phone |
5 | Director Sales - MidSouth | Reveal Email/Phone |
6 | Regional Director | Reveal Email/Phone |
7 | US Finance Operations Director | Reveal Email/Phone |
8 | Director Field Reimbursement | Reveal Email/Phone |
9 | Director Field Reimbursement | Reveal Email/Phone |
10 | Director the CEO office | Reveal Email/Phone |
Kerecis Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $5M | 40 | -18% | $10M | N/A |
#2 | $24.8M | 99 | 29% | N/A | N/A |
#3 | $84.1M | 0 | N/A | $1.2M | N/A |
#4 | $35.6M | 142 | 30% | N/A | N/A |
#5 | $57.5M | 229 | 6% | N/A | N/A |
#6 | $52.7M | 168 | 25% | $129.6M | N/A |
#7 | $21.1M | 84 | -3% | N/A | N/A |
#8 | $61.2M | 244 | -13% | N/A | N/A |
#9 | $60.6M | 193 | 20% | $115.5M | N/A |
#10 | $56.2M | 179 | -3% | $122.9M | N/A |
What Is Kerecis?
Kerecis has developed the unique, patented Kerecisâ„¢ Omega3 fish-skin transplantation technology, where intact fish skin is used for tissue regeneration. The Kerecisâ„¢ Omega3 transplantation technology is used to reconstruct tissue damage such as burn and diabetic wounds as well as for oral wounds, hernia repair, breast reconstruction and for dura restoration. Other tissue-transplant products are based on tissues of human and porcine origin. The Kerecisâ„¢ Omega3 fish skin offers improved economics and clinical performance, as well as reduced disease transfer risk and no cultural constraints on usage. Kerecis' second technology platform is the patented mOmega3 polyunsaturated fatty acid technology, where fatty acids are extracted from fish skin and incorporated in patented dermatological skin treatment products.
keywords:Biotechnology, Medical Devices
$93M
Total Funding
675
Number of Employees
$237.2M
Revenue (est)
63%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Kerecis News
MariGen Expanse, the newest addition to Kerecis' product offerings, supports healing and tissue regeneration in large chronic wounds. Tweet...
Specifically, the partnership will enable Kerecis to participate in Arctic Circle's discussions, assemblies and forums where issues, proposals...
This makes Kerecis medical-fish-skin products available to Healogics Wound Care Centers®, expanding the options to treat chronic, non-healing...
ARLINGTON, Va. & REYKJAVIK, Iceland--(BUSINESS WIRE)--Kerecis Limited, a regenerative-medicine biologics company, has secured $21 million in new financing. Silicon Valley Bank is providing a revolving line of credit of up to $15 million to meet the company’s near-term working-capital needs. Als ...
Kerecis Limited, an Arlington, Va.- and Reykjavik, Iceland-based regenerative-medicine biologics company, secured $21m in financing. Silicon Valley Bank is providing a revolving line of credit of up to $15 million to meet the company’s near-term working-capital needs. The facility is an asset-b ...